Talecris Biotherapeutics

  Home About Talecris Therapeutic Areas Research & Development Donor to Patient Media Center Talecris Careers  
Media Center Overview
Press Releases
Press Releases Archive
News Features
The History of Talecris
Talecris Leadership
Talecris Media Contact Information

Press Releases Archive

2008 Press Releases

2007 Press Releases

2006 Press Releases

2005 Press Releases



2008 Press Releases

  November 18, 2008
The Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
 
  October 15, 2008
Talecris Biotherapeutics Helps Patients Receive Gamunex® During Lapses in Private Insurance Coverage
 
  October 14, 2008
Health Canada Grants Approval to Talecris Biotherapeutics for Gamunex as a Treatment for Neurological Disorder CIDP in Canada
 
  September 23, 2008
Sub-Analysis of Phase III Study Suggests More than Single Treatment may be Required for Therapeutic Response in Some Patients with CIDP
 
  September 23, 2008
Sub-Analysis of Phase III Suggests Long-Term Therapy May Improve Physical and Social Functioning In CIDP Patients
 
  September 18, 2008
Jeffrey Modell Foundation and Talecris Biotherapeutics, Inc. Expand Diagnostic Services for Primary Immunodeficiencies at Children's Hospital Boston
 
  September 15, 2008
FDA Grants Approval to Talecris Biotherapeutics for Gamunex® as a Treatment for Neurological Disorder CIDP in the United States
 
  September 12, 2008
Jeffrey Modell Foundation and Talecris Biotherapeutics Expand Diagnostic Services for Primary Immunodeficiencies at Children's Medical Center
 
  August 20, 2008
Frankfurt University Hospital opens Hessen’s First Centre for Primary Immunodeficiencies
 
  August 12, 2008
Talecris Enters into Definitive Merger Agreement with CSL
 
  July 24, 2008
Talecris Biotherapeutics Receives Orphan Drug Designation for Aerosolized Form of Alpha-1 Antitrypsin (AAT) From the European Commission
 
  June 16, 2008
Talecris Biotherapeutics, Inc. Provides Business Update
 
  May 22, 2008
Talecris Biotherapeutics Awarded MedAssets Supply Chain Systems' Platinum Vendor Designation
 
  May 14, 2008
Talecris Announces 2008 Application Cycle for Talents Research Grants, Presents 2007 Grant Awardees
 
  May 14, 2008
Talecris Announces 2008 Application Cycle for Talents Research Grants, Presents 2007 Grant Awardees
 
  May 08, 2008
FDA Grants Priority Review of Gamunex® as a Treatment for Neurological Disorder CIDP
 
  April 28, 2008
Talecris Partners with Catalent Pharma Solutions for European Contract Manufacturing and Product Testing
 
  April 07, 2008
Die vom global agierenden Biotechnologieunternehmen Talecris Biotherapeutics, Inc. finanzierte „ICE-Studie“ ist die bislang größte veröffentlichte
 
  March 31, 2008
Talecris Biotherapeutics Awarded Manufacturing Contract to Supply Canada with Biological Therapies for the 20th Consecutive Year
 
  March 03, 2008
Jeffrey Modell Foundation and Talecris Biotherapeutics Expand Diagnostic Services for Primary Immunodeficiencies at Lucile Packard Children's Hospital at Stanford
 
  February 21, 2008
Talecris Biotherapeutics Celebrates 20th Anniversary of Launch of Prolastin®
 
  February 13, 2008
Talecris Plasma Resources Reports Solid Progress Developing Plasma Collection Capabilities
 
  February 07, 2008
Positive Results from Phase III Trial of Gamunex® in Patients with CIDP
 
  January 31, 2008
Prolastin.com Receives Gold Award from Association of Marketing and Communication Professionals
 
  January 17, 2008
Precision Pharma Services Merges Into Talecris Biotherapeutics
 


2007 Press Releases

  November 12, 2007
www.Prolastin.com Named Best Biotechnology Web Site of 2007
 
  October 02, 2007
Talecris Announces New Hypermune™ Product Safety Advances
 
  September 18, 2007
Study Demonstrates Aerosolized Prolastin® Using Unique Nebulizer Results in High Levels of Drug Deposited in Peripheral Regions of Lungs
 
  September 16, 2007
Talecris Biotherapeutics awards Winners of the 4th European ALTA Fellowship Program
 
  August 27, 2007
Talecris-Sponsored Scientific Symposium Examines Advances in Use of Intravenous Immune Globulin for Neurological Disorders
 
  August 14, 2007
Gamunex® is Now Latex-Free
 
  August 08, 2007
Talecris Biotherapeutics Debuts CIDPinfo.com for Neurologists and Healthcare Providers
 
  August 02, 2007
Commitment to Patient Access Inspires Talecris Biotherapeutics to Institute a Portability Policy for Gamunex®
 
  July 11, 2007
New Information on the Potential of Plasmin Shared at ISTH Congress
 
  June 12, 2007
Talecris Plasma Resources Supplements Its Collection: Acquisition Adds New Centers
 
  May 08, 2007
Talecris Biotherapeutics’ Talents Program Accepting Applications for 2007 Research Grant Awards
 
  May 03, 2007
Talecris Provides Educational Grant to Support World Federation of Hemophilia’s Global Laboratory Science Program
 
  March 20, 2007
Talecris Initiates Clinical Development Program Evaluating Plasmin for Dissolving Blood Clots and Restoring Blood Flow in Legs
 
  February 23, 2007
Gamunex® is the Preferred Liquid IGIV Therapy Among Allergists and Immunologists Surveyed
 
  February 15, 2007
Talecris’ Product Integrity Enhanced With Environmentally-friendly Shipping Containers
 
  February 13, 2007
Talecris Plasma Resources Opens First New Center in Champaign, Illinois
 
  February 01, 2007
Talecris Biotherapeutics supports projects in the field of Alpha-1-Antitrypsin Deficiency with eALTA fellowships
 
  January 04, 2007
Talecris Names Inaugural Talents Grant Recipients
 


2006 Press Releases

  December 01, 2006
Talecris Continues Global Expansion into Europe
 
  November 20, 2006
Talecris Biotherapeutics Completes Acquisition of Plasma Collection Centers
 
  November 03, 2006
Talecris Biotherapeutics Named a "Fast 50" Company
 
  October 28, 2006
IDF Center of Excellence Dedicated at Duke University
 
  October 26, 2006
New Pediatrician Education Program Launched to Increase Awareness and Improve Diagnosis of Immunodeficiencies in Children
 
  October 09, 2006
Immune Deficiency Foundation Launches Free Electronic Newsletter
 
  October 05, 2006
Talecris Biotherapeutics Celebrates 25 Years of Life-Saving Treatment for People with Primary Immune Deficiency
 
  September 05, 2006
Pathogen Safety Reconfirmed for Prolastin®
 
  September 05, 2006
Extensive Post-License Data Reaffirm Clinical Safety Profile of Prolastin®
 
  September 05, 2006
Talecris Biotherapeutics Awards Third Annual European ALTA Fellowships
 
  August 29, 2006
Bausch & Lomb Licenses rPlasmin from Talecris Biotherapeutics for Ophthalmic Use
 
  June 28, 2006
Talecris Biotherapeutics Announces Start of Licensing Clinical Trials for Alpha-1 Antitrypsin Using Modified Manufacturing Process
 
  May 22, 2006
Landmark Alpha-1 Historical Medical Literature Available from Talecris Biotherapeutics
 
  May 03, 2006
Talecris Biotherapeutics Launches Talents: Talecris New Trials Support Program
 
  April 03, 2006
Talecris Biotherapeutics Announces Global Expansion
 
  January 25, 2006
Grant from Talecris Biotherapeutics Will Support Primary Immunodeficiency Diagnosis and Patient Access to Care
 


2005 Press Releases

  November 09, 2005
Talecris Biotherapeutics' Manufacturing Processes Safeguard Against Avian Bird Flu
 
  November 04, 2005
Talecris Biotherapeutics Showcases Its Clayton Facility to State and Local Dignitaries
 
  October 27, 2005
Talecris Biotherapeutics Strengthens its Executive Leadership Team
 
  October 13, 2005
Talecris Biotherapeutics Initiates Voluntary Recall of Plasmanate®
 
  October 13, 2005
Talecris Celebrates the Second Anniversary of Gamunex®
 
  October 04, 2005
Talecris Biotherapeutics Receives QSEAL Certification from PPTA
 
  September 27, 2005
Talecris Biotherapeutics Awards Second Annual ALTA Fellowships
 
  August 18, 2005
Talecris Announces Extended Room Temperature Storage for Gamunex®
 
  August 09, 2005
Talecris Biotherapeutics and BBI Sign Development Agreement for Alpha-1 Antitrypsin Test
 
  July 07, 2005
Labeling for Gamunex® now Includes Assurances of Removal of Pathogenic Prions During Manufacture
 
  June 16, 2005
Talecris Biotherapeutics Reaffirms Commitment to Set Industry Standard for Product Integrity
 
  May 26, 2005
Talecris Biotherapeutics Becomes First Plasma Fractionator to Perform In-house HBV Screening Using FDA-Licensed Protocol
 
  April 28, 2005
An Evening Symposium held during the European Respiratory Society Annual Congress 2005, Copenhagen
 
  April 01, 2005
Announcing the Launch of Talecris Biotherapeutics: Combining a Proud History of Patient Care with a Bold New Vision
 
  January 07, 2005
Bausch & Lomb To License Plasmin from Bayer HealthCare for Ophthalmic Use
 

 

 

Print This Page
E-mail This Page
News & Events
See how Talecris is being recognized for innovation and commitment.
Learn More

Talecris Biotherapeutics
Contact Talecris    Glossary    Site Map
General Conditions of Use    Privacy Statement    California Compliance
© 2008 Talecris Biotherapeutics